Resistance to androgen receptor (AR)-targeted therapies in prostate cancer (PC) is a major clinical problem. A key mechanism of treatment resistance in advanced PC is the generation of alternatively spliced forms of the AR termed AR variants (AR-Vs) that are refractory to targeted agents and drive tumour progression. Our understanding of how AR-Vs function is limited due to difficulties in distinguishing their discriminate activities from full-length AR (FL-AR). The CWR22Rv1-AR-EK (Androgen Receptor-Exon Knockout) cell line is a prostate cancer cell line which is knockout for FL-AR (by CRISPR) but retains expression of all endogenous AR-Vs making it a valuable model…
| Inventor | Institute |
|---|---|
| Luke Gaughan | Newcastle University |
| SKU: | 154854 |
|---|---|
| Product description: | Resistance to androgen receptor (AR)-targeted therapies in prostate cancer (PC) is a major clinical problem. A key mechanism of treatment resistance in advanced PC is the generation of alternatively spliced forms of the AR termed AR variants (AR-Vs) that are refractory to targeted agents and drive tumour progression. Our understanding of how AR-Vs function is limited due to difficulties in distinguishing their discriminate activities from full-length AR (FL-AR).The CWR22Rv1-AR-EK (Androgen Receptor-Exon Knockout) cell line is a prostate cancer cell line which is knockout for FL-AR (by CRISPR) but retains expression of all endogenous AR-Vs making it a valuable model for the study of receptor splice variants. This new derivative is dependent upon AR-Vs for growth and is refractory to all FL-AR-targeting agents. CRISPR edited CWR22Rv1 cells. |
| Alternate name: | AR-V |
| Conditional: | No |
| Production details: | CRISPR-derived cell line that has lost expression of full length androgen receptor (FL-AR), but retains all endogenous androgen receptor variants (AR-Vs). Two gRNAs were designed to target distinct loci within exon 5 of the AR gene. To knock-in a stop codon into exon 5 of the AR locus, a 180 bp ssODN template was designed containing a central TAA sequence and flanked by 75 bp 5ÄË?Â? and 3ÄË?Â? termini 100% complementary to the AR gene sequence. |
| Additional notes: | CRISPR edited CWR22Rv1 cells. Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here. This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can pr… |
| Parental cell line: | CWR22Rv1 |
| Disease: | Cancer |
| Cat. #: | 154854 |
|---|---|
| Tool sub type: | Continuous |
| Unit size: | 1×10^6 cells / vial |
| Cancer types: | Prostate cancer |
| Research Fields: | Cancer; Drug development |
| Organism: | Human |
| Model: | Knock-In |
| Cancer Types In Detail: | Prostate |
| Format: | Frozen |
|---|---|
| Storage conditions: | Liquid Nitrogen |
| Shipping conditions: | Dry ice |
| Growth medium: | RPMI 1640 media supplemented with 10% foetal calf serum (FCS) and 5% L-glutamine at 37?°C |
| Recommended controls: | CWR22Rv1 parental line |
| Mycoplasma free: | Yes |
| Biosafety level: | 1 |
| References: |
Kounatidou et al. 2019. Nucleic Acids Res. 47(11):5634-5647. PMID: 31006810. |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.